Literature DB >> 17263291

Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the western Cape of South Africa.

T C Victor1, E M Streicher, C Kewley, A M Jordaan, G D van der Spuy, M Bosman, H Louw, M Murray, D Young, P D van Helden, R M Warren.   

Abstract

BACKGROUND: South Africa has a high burden of drug-resistant tuberculosis (TB).
METHODS: Routine drug susceptibility testing was performed prospectively over a 2-year period on Mycobacterium tuberculosis isolates in two health districts of the Western Province, South Africa. A cluster of drug-resistant strains that shared a rare mutation in katG315 was found in 64 of the 450 cases identified as having been infected with drug-resistant TB. Isolates belonging to this cluster were phenotypically and genotypically characterised. Epidemiological and clinical characteristics were used to identify mechanisms leading to the acquisition and spread of this drug-resistant strain.
RESULTS: An outbreak of an emerging non-Beijing drug-resistant strain infecting 64 pulmonary tuberculosis (PTB) cases was identified. This previously undetected genotype (now designated DRF150) is characterised by five IS6110 insertions, specific spoligotypes and high levels of resistance to the first-line TB medications isoniazid, streptomycin and rifampicin. In 45% of the cases it is also resistant to ethambutol and pyrazinamide. Key factors leading to the development and spread of this drug-resistant genotype were inappropriate chemotherapy, poor adherence to treatment and prolonged periods of infectiousness due to delays in susceptibility testing.
CONCLUSIONS: Molecular markers allowed early identification of an emerging non-Beijing drug-resistant strain.

Entities:  

Mesh:

Year:  2007        PMID: 17263291

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  25 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent.

Authors:  Pieter W Uys; Robin Warren; Paul D van Helden; Megan Murray; Thomas C Victor
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

4.  Fitness-compensatory mutations facilitate the spread of drug-resistant F15/LAM4/KZN and F28 Mycobacterium tuberculosis strains in KwaZulu-Natal, South Africa.

Authors:  Charissa C Naidoo; Manormoney Pillay
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

5.  Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.

Authors:  Neel R Gandhi; Darren Weissman; Prashini Moodley; Melissa Ramathal; Inga Elson; Barry N Kreiswirth; Barun Mathema; Elena Shashkina; Richard Rothenberg; Anthony P Moll; Gerald Friedland; A Willem Sturm; N Sarita Shah
Journal:  J Infect Dis       Date:  2012-11-19       Impact factor: 5.226

6.  Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia.

Authors:  Stefan Niemann; Roland Diel; George Khechinashvili; Medea Gegia; Nino Mdivani; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2010-08-11       Impact factor: 5.948

7.  Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.

Authors:  E M Streicher; I Bergval; K Dheda; E C Böttger; N C Gey van Pittius; M Bosman; G Coetzee; R M Anthony; P D van Helden; T C Victor; R M Warren
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

8.  Evidence for waning of latency in a cohort study of tuberculosis.

Authors:  Harald G Wiker; Tehmina Mustafa; Gunnar A Bjune; Morten Harboe
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

9.  Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa.

Authors:  Alistair D Calver; Alecia A Falmer; Megan Murray; Odelia J Strauss; Elizabeth M Streicher; Madelene Hanekom; Thelma Liversage; Mothusi Masibi; Paul D van Helden; Robin M Warren; Thomas C Victor
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

10.  Sulfatase-activated fluorophores for rapid discrimination of mycobacterial species and strains.

Authors:  Kimberly E Beatty; Monique Williams; Brian L Carlson; Benjamin M Swarts; Robin M Warren; Paul D van Helden; Carolyn R Bertozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.